Top

Drugs

Published in:

01-10-2006 | Adis Drug Profiles

Tramadol Extended-Release Tablets

A Viewpoint by Bill H. McCarberg

Author: Bill H. McCarberg

Published in: Drugs | Issue 15/2006

Excerpt

Tramadol is an oral analgesic that has been approved in the US for >10 years and in Europe for >30 years for the management of moderate to moderately severe pain. While the efficacy and safety of immediate-release tramadol are well established, the requirement of administration every 4–6 hours[1] makes this formulation less than optimal for the long-term management of chronic pain, due to the possible lack of continuous analgesic coverage throughout the day and night. Additionally, the repeated peaks and troughs in tramadol levels that occur with frequent administration may be associated with a higher incidence of adverse effects. …

The use of trade names is for product identification purposes only and does not imply endorsement.

ULTRAM® (tramadol hydrochloride tablets). US prescribing information May 2004. Ortho-McNeil Pharmaceutical, Inc., Raritan (NJ) [online]. Available from URL: http://www.ortho-mcneil.com [Accessed 2006 Oct 2]

American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000; 43(9): 1905–15CrossRef

Hudson L, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib or non-steroidal anti-inflammatory drugs: population based study. BMJ 2005 Jun 11; 330(7504): 1370PubMedCrossRef

Caldwell B, Aldington S, Weatherall M, et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006; 99(3): 132–40PubMedCrossRef

National Pharmaceutical Council, Inc., Joint Commission on Accreditation of Healthcare Organizations. Pain: current understanding of assessment, management, and treatments. Reston (VA): National Pharmaceutical Council, Inc., 2001 [online]. Available from URL: http://www.npcnow.org/resources/PDFs/painmonograph.pdf [Accessed 2006 Sep 26]

Weinstein SM, Laux LF, Thornby JI, et al. Physicians’ attitudes toward pain and the use of opioid analgesics: results of a survey from the Texas Cancer Pain Initiative. South Med J 2000; 93(5): 479–87PubMed

ULTRAM® ER (tramadol HCl) extended-release tablets. US prescribing information January 2006. Ortho-McNeil, Inc., Raritan (NJ) [online]. Available from URL: http://www.ortho-mcneil.com [Accessed 2006 Oct 2]

Babul N, Noveck R, Chipman H, et al. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage 2004; 28(1): 59–71PubMedCrossRef

Gana TJ, Pascual ML, Fleming RR. Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial. 023 Study Group. Curr Med Res Opin 2006; 22(7): 1391–401PubMedCrossRef

Title: Tramadol Extended-Release Tablets
A Viewpoint by Bill H. McCarberg
Author: Bill H. McCarberg
Publication date: 01-10-2006
Publisher: Springer International Publishing
Published in: Drugs / Issue 15/2006
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200666150-00017

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Tramadol Extended-Release Tablets

A Viewpoint by Bill H. McCarberg

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 15/2006

Panitumumab

Panitumumab

Tramadol Extended-Release Tablets

Familial Dyslipidaemias

Optimising Antiresorptive Therapies in Postmenopausal Women

Tramadol Extended-Release Tablets